Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products

Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products

US Patent 6346249 · Granted Feb 12, 2002

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Humanized and variant TGF-β1 specific antibodies and methods and uses thereof2025
Anti-CTLA-4 antibodies and methods of use thereof2025
Antibody compounds with reactive arginine and related antibody drug conjugates2025
Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeri2025
Anti-CTLA-4 antibodies and methods of use thereof2025
Antibodies and methods of use thereof2024
Treatment of cancer using GFR alpha-4 chimeric antigen receptor2024
Anti-GITR antibodies and methods of use thereof2024
ROR2 antibody compositions and related methods2023
Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeri2023
Anti-CTLA-4 antibodies and methods of use thereof2023
Methods of administering anti-OX40 antibodies2022